Extrahepatic Feeding of HCC Limits the Use of TACE? Evidences from Literature and Clinical Experience


Trans-arterial chemoembolization (TACE) has been established as the standard of care for patients with intermediate stage of multinodular hepatocellular carcinoma (HCC), according to Barcelona Clinic Liver Cancer (BCLC) classification, and no extra-hepatic diffusion. The efficacy and safety of the procedure are related to the possibility of performing a superselective catheterization of the branches of the hepatic artery responsible for the vascularisation of the tumour. However, in some cases, the vascularisation of the nodules can be complex and arterial supply can derive from vessels originating from the extra-hepatic circulation. This condition, called extra-hepatic feeding, is not a rare finding, and can hamper the therapeutic efficacy of TACE. When investigating a candidate for TACE, anamnestic and radiological elements suggestive for the presence of extra-collateral arteries should be known and taken into account. Once diagnosed, although extra-hepatic feeding does not represent an absolute contraindication to TACE, it requires, in each case, a careful benefit-risk assessment, being impossible to establish a standard procedure. We here present a review of the available literature and a paradigmatic case of multifocal HCC with an extra-hepatic feeding.

Share and Cite:

A. Tovoli, L. Napoli, M. Mastroroberto, M. Renzulli, M. Tufoni, C. Ricci, R. Golfieri and G. Brandi, "Extrahepatic Feeding of HCC Limits the Use of TACE? Evidences from Literature and Clinical Experience," Journal of Cancer Therapy, Vol. 4 No. 2A, 2013, pp. 413-419. doi: 10.4236/jct.2013.42A050.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] J. M. Llovet, “Updated Treatment Approach to Hepatocellular Carcinoma,” Journal of Gastroenterology, Vol. 40, No. 3, 2005, pp. 225-235. doi:10.1007/s00535-005-1566-3
[2] A. Sangiovanni, G. M. Prati, P. Fasani, et al., “The Natural History of Compensated Cirrhosis Due to Hepatitis C Virus: A 17-Year Cohort Study of 214 Patients,” Hepatology, Vol. 43, No. 6, 2006, pp. 1303-1310. doi:10.1002/hep.21176
[3] European Association for Study of Liver, European Organization for Research and Treatment of Cancer, “EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma,” European Journal of Cancer, Vol. 48, No. 5, 2012, pp. 599-641. doi:10.1016/j.ejca.2011.12.021
[4] A. Guglielmi, A. Ruzzenente, S. Pachera, et al., “Comparison of Seven Staging Systems in Cirrhotic Patients with Hepatocellular Carcinoma in a Cohort of Patients Who Underwent Radiofrequency Ablation with Complete Response,” American Journal of Gastroenterology, Vol. 103, No. 3, 2008, pp. 597-604. doi:10.1111/j.1572-0241.2007.01604.x
[5] J. H. Kim, J. W. Chung, J. K. Han, et al., “Transcatheter Arterial Embolization of the Internal Mammary Artery in Hepatocellular Carcinoma,” Journal of Vascular and Interventional Radiology, Vol. 6, No. 1, 1995, pp. 71-77. doi:10.1016/S1051-0443(95)71059-4
[6] L. F. Cheng, K. F. Ma, W. C. Fan, et al., “Hepatocellular Carcinoma with Extrahepatic Collateral Arterial Supply,” Journal of Medical Imaging and Radiation Oncology, Vol. 54, No. 1, 2010, pp. 26-34. doi:10.1111/j.1754-9485.2010.02134.x
[7] S. B. Paul, S. R. Gamanagatti, A. Mukund, et al., “Transarterial Chemoembolization for Hepatocellular Carcinoma: Significance of Extrahepatic Collateral Supply,” Indian Journal of Cancer, Vol. 48, No. 3, 2011, pp. 339-344. doi:10.4103/0019-509X.84941
[8] C. M. Lo, H. Ngan, W. K. Tso, et al., “Randomized Controlled Trial of Transarterial Lipiodol Chemoembolization for Unresectable Hepatocellular Carcinoma,” Hepatology, Vol. 35, No. 5, 2002, pp. 1164-1171. doi:10.1053/jhep.2002.33156
[9] J. M. Llovet, M. I. Real, X. Montana, et al., “Arterial Embolisation or Chemoembolisation versus Symptomatic Treatment in Patients with Unresectable Hepatocellular Carcinoma: A Randomised Controlled Trial,” Lancet, Vol. 359, No. 9319, 2002, pp. 1734-1739. doi:10.1016/S0140-6736(02)08649-X
[10] R. Lencioni, “Chemoembolization for Hepatocellular Carcinoma,” Seminars in Oncology, Vol. 39, No. 4, 2012, pp. 503-509. doi:10.1053/j.seminoncol.2012.05.004
[11] T. Gunji, N. Kawauchi, M. Akahane, et al., “Long-Term Outcomes of Transcatheter Arterial Chemoembolization with Autologous Blood Clot for Unresectable Hepatocellular Carcinoma,” International Journal of Oncology, Vol. 21, No. 2, 2002, pp. 427-432.
[12] J. A. Marrero, R. J. Fontana, A. Barrat, et al., “Prognosis of Hepatocellular Carcinoma: Comparison of 7 Staging Systems in an American Cohort,” Hepatology, Vol. 41, No. 4, 2005, pp. 707-716. doi:10.1002/hep.20636
[13] T. Konno, “Targeting Cancer Chemotherapeutic Agents by Use of Lipiodol Contrast Medium,” Cancer, Vol. 66, No. 9, 1990, pp. 1897-1903. doi:10.1002/1097-0142(19901101)66:9<1897::AID-CNCR2820660907>3.0.CO;2-J
[14] R. Golfieri, A. Cappelli, A. Cucchetti, et al., “Efficacy of Selective Transarterial Chemoembolization in Inducing Tumor Necrosis in Small (<5 cm) Hepatocellular Carcinomas,” Hepatology, Vol. 53, No. 5, 2011, pp. 1580-1589. doi:10.1002/hep.24246
[15] D. Y. Lin, Y. F. Liaw, T. Y. Lee, et al., “Hepatic Arterial Embolization in Patients with Unresectable Hepatocellular Carcinoma—A Randomized Controlled Trial,” Gastroenterology, Vol. 94, No. 2, 1988, pp. 453-456.
[16] G. Pelletier, A. Roche, O. Ink, et al., “A Randomized Trial of Hepatic Arterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma,” Journal of Hepatology, Vol. 11, No. 2, 1990, pp. 181-184. doi:10.1016/0168-8278(90)90110-D
[17] Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire, “A Comparison of Lipiodol Chemoembolization and Conservative Treatment for Unresectable Hepatocellular Carcinoma,” New England Journal of Medicine, Vol. 332, No. 19, 1995, pp. 1256-1261. doi:10.1056/NEJM199505113321903
[18] J. Bruix, J. M. Llovet, A. Castells, et al., “Transarterial Embolization versus Symptomatic Treatment in Patients with Advanced Hepatocellular Carcinoma: Results of a Randomized, Controlled Trial in a Single Institution,” Hepatology, Vol. 27, No. 1, 1998, pp. 1578-1583. doi:10.1002/hep.510270617
[19] G. Pelletier, M. Ducreux, F. Gay, et al., “Treatment of Unresectable Hepatocellular Carcinoma with Lipiodol Chemoembolization: A Multicenter Randomized Trial. Groupe CHC,” Journal of Hepatology, Vol. 29, No. 1, 1998, pp. 129-134. doi:10.1016/S0168-8278(98)80187-6
[20] J. W. Chung, H. C. Kim, J. H. Yoon, et al., “Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma: Prevalence and Causative Factors of Extrahepatic Collateral Arteries in 479 Patients,” Korean Journal of Radiology, Vol. 7, No. 4, 2006, pp. 257-266. doi:10.3348/kjr.2006.7.4.257
[21] H. C. Kim, J. W. Chung, W. Lee, et al., “Recognizing Extrahepatic Collateral Vessels that Supply Hepatocellular Carcinoma to Avoid Complications of Transcatheter Arterial Chemoembolization,” Radiographics, Vol. 25, 2005, pp. S25-S39. doi:10.1148/rg.25si055508
[22] C. R. Davis, “Interventional Radiological Treatment of Hepatocellular Carcinoma,” Cancer Control, Vol. 17, No. 2, 2010, pp. 87-99.
[23] S. Miyayama, M. Yamashiro, M. Okuda, et al., “The March of Extrahepatic Collaterals: Analysis of Blood Supply to Hepatocellular Carcinoma Located in the Bare Area of the Liver After Chemoembolization,” CardioVascular and Interventional Radiology, Vol. 33, No. 3, 2010, pp. 513-522. doi:10.1007/s00270-009-9697-1
[24] C. Li, Y. Guo, G. Tian, et al., “Extrahepatic Arterial Blood Supply of Hepatocellular Carcinoma and Interventional Treatment,” Chinese Journal of Oncology, Vol. 24, No. 2, 2002, pp. 163-166.
[25] J. W. Chung, J. H. Park, J. K. Han, et al., “Transcatheter Oily Chemoembolization of the Inferior Phrenic Artery in Hepatocellular Carcinoma: The Safety and Potential Therapeutic Role,” Journal of Vascular and Interventional Radiology, Vol. 9, No. 3, 1998, pp. 495-500. doi:10.1016/S1051-0443(98)70306-9
[26] M. Okazaki, S. Yamasaki, H. Ono, et al., “Chemoembolotherapy for Recurrent Hepatocellular Carcinoma in the Residual Liver after Hepatectomy,” Hepatogastroenterology, Vol. 40, No. 4, 1993, pp. 320-323.
[27] Y. L. Wang, M. H. Li, Y. S. Cheng, et al., “Influential Factors and Formation of Extrahepatic Collateral Artery in Unresectable Hepatocellular Carcinoma,” World Journal of Gastroenterology, Vol. 11, No. 17, 2005, pp. 2637-2642.
[28] K. H. Lee, K. B. Sung, D. Y. Lee, et al., “Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Anatomic and Hemodynamic Considerations in the Hepatic Artery and Portal Vein,” Radiographics, Vol. 22, No. 5, 2002, pp. 1077-1091.
[29] C. Charnsangavej, V. P. Chuang, S. Wallace, et al., “Angiographic Classification of Hepatic Arterial Collaterals,” Radiology, Vol. 144, No. 3, 1982, pp. 485-494.
[30] Y. Okino, H. Kiyosue, S. Matsumoto, et al., “Hepatocellular Carcinoma: Prediction of Blood Supply from Right Inferior Phrenic Artery by Multiphasic CT,” Journal of Computer Assisted Tomography, Vol. 27, No. 3, 2003, pp. 341-346. doi:10.1097/00004728-200305000-00007
[31] T. Shibata, N. Kojima, T. Tabuchi, et al., “Transcatheter Arterial Chemoembolization through Collateral Arteries for Hepatocellular Carcinoma after Arterial occlusion,” Radiation Medicine, Vol. 16, No. 4, 1998, pp. 251-256.
[32] S. Miyayama, O. Matsui, H. Nishida, et al., “Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma Fed by the Cystic Artery,” Journal of Vascular and Interventional Radiology, Vol. 14, No. 9, 2003, pp. 1155-1161. doi:10.1097/01.RVI.0000086534.86489.10
[33] J. Y. Won, D. Y. Lee, J. T. Lee, et al., “Supplemental Transcatheter Arterial Chemoembolization through a Collateral Omental Artery: Treatment for Hepatocellular Carcinoma,” CardioVascular and Interventional Radiology, Vol. 26, No. 2, 2003, pp. 136-140. doi:10.1007/s00270-002-2629-y
[34] M. Nakai, M. Sato, N. Kawai, et al., “Hepatocellular Carcinoma: Involvement of the Internal Mammary Artery,” Radiology, Vol. 219, No. 1, 2001, pp. 147-152.
[35] S. I. Park, D. Y. Lee, J. Y. Won, et al., “Extrahepatic Collateral Supply of Hepatocellular Carcinoma by the Intercostal Arteries,” Journal of Vascular and Interventional Radiology, Vol. 14, No. 4, 2003, pp. 461-468. doi:10.1097/01.RVI.0000064856.87207.1E
[36] J. W. Chung, J. H. Park, J. K. Han, et al., “Hepatic Tumors: Predisposing Factors for Complications of Transcatheter Oily Chemoembolization,” Radiology, Vol. 198, No. 1, 1996, pp. 33-40.
[37] R. Arora, M. C. Soulen and Z. J. Haskal, “Cutaneous Complications of Hepatic Chemoembolization via Extrahepatic Collaterals,” Journal of Vascular and Interventional Radiology, Vol. 10, No. 10, 1999, pp. 1351-1356. doi:10.1016/S1051-0443(99)70242-3
[38] J. H. Lee, C. Y. Chon, S. H. Ahn, et al., “An Ischemic Skin Lesion after Chemoembolization of the Right Internal Mammary Artery in a Patient with Hepatocellular Carcinoma,” Yonsei Medical Journal, Vol. 42, No. 1, 2001, pp. 137-141.
[39] M. Hirakawa, M. Iida, K. Aoyagi, et al., “Gastroduodenal Lesions after Transcatheter Arterial Chemo-Embolization in Patients with Hepatocellular Carcinoma,” American Journal of Gastroenterology, Vol. 83, No. 8, 1988, pp. 837-840.
[40] S. Miyayama, O. Matsui, K. Taki, et al., “Extrahepatic Blood Supply to Hepatocellular Carcinoma: Angiographic Demonstration and Transcatheter Arterial Chemoembolization,” CardioVascular and Interventional Radiology, Vol. 29, No. 1, 2006, pp. 39-48. doi:10.1007/s00270-004-0287-y
[41] I. Sakamoto, N. Aso, K. Nagaoki, et al., “Complications Associated with Transcatheter Arterial Embolization for Hepatic Tumors,” Radiographics, Vol. 18, No. 3, 1998, pp. 605-619.
[42] O. Matsui, M. Kadoya, J. Yoshikawa, et al., “Small Hepatocellular Carcinoma: Treatment with Subsegmental Transcatheter Arterial Embolization,” Radiology, Vol. 188, No. 1, 1993, pp. 79-83.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.